Larazotide

What is Larazotide?

Larazotide acetate (also known as AT-1001) is an investigational synthetic peptide designed to regulate tight junctions in the intestinal epithelium. It belongs to a class of compounds known as zonulin antagonists, meaning it works by blocking the activity of zonulin, a protein that modulates the permeability of tight junctions between cells lining the gut. By inhibiting zonulin, larazotide may help restore the integrity of the intestinal barrier and reduce the passage of harmful substances through the gut wall.

Originally developed by Alba Therapeutics, the compound was later acquired by Innovate Biopharmaceuticals, which subsequently merged with 9 Meters Biopharma. Larazotide has been primarily investigated as a treatment for celiac disease, a chronic autoimmune disorder triggered by gluten ingestion that affects approximately 1% of the global population. The compound has progressed through multiple phases of clinical trials, reaching Phase 3 status, making it one of the most advanced non-dietary therapies for celiac disease under investigation.

As of the current date, larazotide has not received FDA approval. It remains an investigational compound and is not available as a prescription medication. Its mechanism of action is unique among celiac disease therapies because it targets the paracellular pathway rather than attempting to degrade gluten or suppress the immune response directly. Larazotide is administered orally as a capsule and acts locally within the gastrointestinal tract, with minimal systemic absorption.

Clinical Research & Evidence

Larazotide has been evaluated in several clinical trials spanning Phase 1 through Phase 3. Early Phase 1 and Phase 2 studies demonstrated that the compound was generally well-tolerated and showed signals of efficacy in reducing symptoms associated with gluten exposure in celiac disease patients. In a Phase 2b trial published in Gastroenterology, larazotide acetate at a dose of 0.5 mg three times daily showed a statistically significant reduction in celiac disease symptoms compared to placebo in patients who were already following a gluten-free diet but still experiencing symptoms.

Research suggests that larazotide may be particularly beneficial for the large number of celiac disease patients who continue to experience symptoms despite strict adherence to a gluten-free diet. Studies indicate that up to 40-50% of celiac patients on a gluten-free diet still report persistent gastrointestinal symptoms, and larazotide addresses this unmet medical need by reducing intestinal permeability caused by inadvertent gluten exposure.

A Phase 3 clinical trial was initiated to further evaluate the efficacy and safety of larazotide in a larger patient population. The trial aimed to assess the compound's ability to reduce symptoms in celiac disease patients on a gluten-free diet. Results from this pivotal study are being used to support potential regulatory submissions. Preclinical and early clinical data also suggest that the compound's mechanism of action could have broader implications for other conditions involving increased intestinal permeability, though celiac disease remains the primary target indication.

Additional research has explored the role of zonulin and intestinal permeability in conditions beyond celiac disease, including type 1 diabetes, inflammatory bowel disease, and irritable bowel syndrome. While larazotide has not been formally studied in large-scale trials for these indications, the underlying science suggests potential therapeutic applications that may be explored in future research programs.

Potential Benefits

• Tight Junction Regulation: Research suggests larazotide may help restore and maintain the integrity of intestinal tight junctions, reducing abnormal permeability in the gut lining.
• Reduced Intestinal Permeability: By antagonizing zonulin, larazotide may decrease the paracellular passage of gluten fragments and other antigens through the intestinal wall.
• Celiac Disease Symptom Relief: Clinical trials suggest that larazotide may reduce gastrointestinal symptoms such as abdominal pain, bloating, and diarrhea in celiac disease patients on a gluten-free diet.
• Non-Immunosuppressive Mechanism: Unlike many autoimmune therapies, larazotide works by strengthening the gut barrier rather than suppressing the immune system, which may result in a more favorable safety profile.
• Local Gut Action: The compound acts primarily within the gastrointestinal tract with minimal systemic absorption, potentially reducing the risk of systemic side effects.
• Oral Administration: Larazotide is taken as an oral capsule, making it convenient and non-invasive compared to injectable therapies.
• Adjunct to Gluten-Free Diet: Studies indicate larazotide may serve as a complementary therapy to the gluten-free diet, providing additional protection against inadvertent gluten exposure.
• Potential Broader Applications: The mechanism of regulating intestinal permeability may have implications for other conditions associated with "leaky gut," though further research is needed.

Dosing Protocol

Note: Larazotide is an investigational compound and is not commercially available. The dosing information above reflects protocols used in clinical trials. In Phase 2 studies, doses of 0.25 mg, 0.5 mg, 1 mg, and 4 mg were evaluated, with 0.5 mg three times daily showing the most favorable efficacy signal. The capsule is typically taken 15 minutes before meals to provide barrier protection prior to potential gluten exposure.

Reconstitution Guide

Larazotide is administered as a pre-formulated oral capsule. No reconstitution, mixing, or preparation is required. The capsule is taken whole with water, typically 15 minutes before meals. Do not open, crush, or chew the capsule unless specifically directed by a healthcare provider or clinical trial protocol.

Half-Life & Pharmacokinetics

Larazotide acts locally within the gastrointestinal tract and is designed to have minimal systemic absorption. Because the compound exerts its therapeutic effects at the intestinal epithelial surface rather than through systemic circulation, traditional pharmacokinetic parameters such as plasma half-life are less relevant to its mechanism of action. The peptide is largely degraded within the GI tract by digestive enzymes.

Studies indicate that systemic exposure to larazotide is extremely low, with plasma concentrations often below the limit of quantification. This local mode of action is considered advantageous from a safety perspective, as it limits the potential for systemic side effects. The rapid degradation of the peptide in the gut means that dosing before each meal is necessary to maintain barrier protection throughout the day.

Administration Guide

Larazotide is an oral compound administered as a capsule. No injection is required. The following guidelines reflect protocols used in clinical trials:

• Take the capsule approximately 15 minutes before meals with a full glass of water
• The standard clinical trial regimen involves dosing three times daily (before breakfast, lunch, and dinner)
• Swallow the capsule whole; do not open, crush, or chew
• Maintain your gluten-free diet as directed by your healthcare provider; larazotide is intended as an adjunct, not a replacement for dietary management
• Store capsules at room temperature in their original packaging until use
• If a dose is missed, take it as soon as remembered before the next meal; do not double up on doses

Side Effects & Safety

Clinical trials have generally reported that larazotide is well-tolerated, with a side-effect profile similar to placebo in many studies. Common adverse events reported in trials include:

• Headache (mild, reported at similar rates to placebo)
• Nausea (generally mild and transient)
• Abdominal pain (may be difficult to distinguish from underlying celiac symptoms)
• Diarrhea (reported at low rates)
• Upper respiratory tract infection (reported in some trial participants)
• Urinary tract infection (reported at low incidence)

Stacking & Interactions

Because larazotide acts locally in the gut with minimal systemic absorption, the potential for systemic drug-drug interactions is considered low. However, formal drug interaction studies are limited. Always inform your healthcare provider of all medications and supplements you are taking.

Storage & Handling

Larazotide capsules should be stored under the following conditions:

• Temperature: Store at controlled room temperature (20-25°C / 68-77°F)
• Protection: Keep in original packaging to protect from moisture and light
• Humidity: Avoid exposure to high humidity; do not store in bathrooms
• Travel: Capsules are stable at room temperature, making them convenient for travel; keep in original container with desiccant if provided
• Shelf life: Follow the expiration date printed on the packaging; do not use after expiration
• Disposal: Dispose of expired or unused capsules according to local pharmaceutical waste guidelines

Legal & Regulatory Status

Larazotide acetate is classified as an investigational new drug (IND) and has not received FDA approval for any indication. It is currently available only through clinical trials or expanded access programs where applicable. The compound has received Fast Track designation from the FDA for the treatment of celiac disease, reflecting the agency's recognition of the unmet medical need in this patient population.

Larazotide is not a controlled substance and does not appear on any DEA scheduling lists. However, because it is not approved, it cannot be legally prescribed, dispensed, or sold outside of a clinical trial or investigational setting. Patients interested in accessing larazotide should consult with their healthcare provider about potential clinical trial enrollment opportunities through 9 Meters Biopharma or ClinicalTrials.gov.

Recommended Bloodwork & Monitoring

While larazotide acts locally in the gut and may require less systemic monitoring than many medications, the following tests are commonly used to track celiac disease activity and overall gut health in the context of treatment:

• Tissue Transglutaminase (tTG-IgA): Standard marker for celiac disease activity; monitor at baseline and periodically during treatment
• Deamidated Gliadin Peptide (DGP) Antibodies: Supplementary celiac marker, especially useful in patients with IgA deficiency
• Total IgA: Baseline test to rule out IgA deficiency, which can cause false-negative celiac serologies
• Complete Blood Count (CBC): To assess for anemia, which is common in celiac disease due to malabsorption
• Iron Studies (Ferritin, TIBC): Iron deficiency is a common complication of celiac disease
• Vitamin D and Calcium: Malabsorption may lead to deficiencies; monitor and supplement as needed
• Folate and Vitamin B12: May be affected by intestinal damage from celiac disease
• Liver Function Tests: Elevated transaminases can occur in untreated celiac disease

Frequently Asked Questions

Related Compounds